CINQAIR 10 mg/mL
Reslizumab · INJECTION, SOLUTION, CONCENTRATE · Teva Respiratory, LLC
No Recall History
Plain English
CINQAIR is a injection, solution, concentrate containing reslizumab at 10 mg/mL, taken intravenous. Manufactured by Teva Respiratory, LLC.
Key Facts
- Brand Name
- CINQAIR
- Generic Name
- Reslizumab
- NDC Code (Product)
59310-610- Manufacturer
- Teva Respiratory, LLC
- Strength
- 10 mg/mL
- Dosage Form
- INJECTION, SOLUTION, CONCENTRATE
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761033
- Drug Class
- Interleukin-5 Antagonist [EPC]
- Marketing Start
- 04/18/2016
Recall History
No Recall HistoryFrequently Asked Questions
What is CINQAIR used for?
CINQAIR contains Reslizumab. It is a injection, solution, concentrate taken intravenous. Consult your doctor for specific uses.
Is CINQAIR a controlled substance?
CINQAIR is not classified as a controlled substance by the DEA.
What is the generic name for CINQAIR?
The generic name for CINQAIR is Reslizumab. There are no other listed brand versions of Reslizumab.
What is the NDC code for CINQAIR 10 mg/mL?
The NDC (National Drug Code) for CINQAIR 10 mg/mL is 59310-610, listed by Teva Respiratory, LLC.
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)